NOVOCURE INC.

Novocure Inc. specializes in the design, manufacturing, and delivery of electromedical and electrophysical therapeutic devices, with a primary focus on tumor-treating fields (TTFields) technology for chronic disease management. The company provides FDA-regulated medical systems and associated transducer arrays used in oncology care, particularly for conditions such as glioblastoma and mesothelioma. Their technical expertise lies in low-intensity, alternating electric field delivery systems, patient-worn wearable platforms, and the integration of medical-grade electronics with clinical workflows. Key differentiators include proprietary non-invasive therapy delivery mechanisms, rigorous adherence to medical device quality standards, and a strong emphasis on patient compliance and continuous therapy monitoring. The contractor maintains an extensive and consistent relationship with the Department of Veterans Affairs, supplying critical therapeutic devices and consumables under prosthetics and durable medical equipment programs. Work with the VA centers on the ongoing provision of OPTUNE systems and transducer renewals, indicating a long-term, repeat-service model focused on sustaining chronic care regimens for veteran patients. There is no evidence of engagement with other federal agencies beyond the VA. Novocure’s primary industry focus is in NAICS 334510—electromedical and electrophysical apparatus manufacturing—where they position themselves as a niche provider of advanced, non-pharmacological cancer therapies. Secondary activity in surgical appliance and instrument manufacturing (339113 and 339112) supports device accessory and consumable production, reinforcing their vertical integration in patient-specific therapeutic systems. As a small business structured as a 2L entity based in Portsmouth, NH, Novocure operates without federal certifications such as 8(a), HUBZone, or SDVOSB. Their government market presence is narrowly focused on the VA’s prosthetics and medical equipment supply chain, with no indication of broader federal or DoD engagement. The company’s capabilities are deeply specialized, serving a highly regulated therapeutic segment within the federal healthcare ecosystem.